Pieris Pharmaceuticals Inc (PIRS) was Resumed by ROTH Capital to “Buy”. ROTH Capital advised their investors in a research report released on Aug 5, 2016.
Pieris Pharmaceuticals Inc closed down -0.03 points or -1.73% at $1.7 with 74,483 shares getting traded on Thursday. Post opening the session at $1.73, the shares hit an intraday low of $1.7 and an intraday high of $1.76 and the price fluctuated in this range throughout the day.Shares ended Thursday session in Red.
In a different news, on Jun 15, 2016, Stephen S. Yoder (CEO) purchased 6,000 shares at $1.68 per share price. According to the SEC, on Jun 15, 2016, Darlene M Deptula-hicks (CFO) purchased 5,000 shares at $1.66 per share price. On Jun 15, 2016, Louis Matis (SVP, Chief Development Officer) purchased 10,000 shares at $1.70 per share price, according to the Form-4 filing with the securities and exchange commission.
Pieris Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of Anticalin class of biotherapeutics for patients with diseases. The Company is focused on developing two drug candidates PRS-080 and PRS-060. PRS-080 is an Anticalin protein that binds to hepcidin a natural regulator of iron in the blood. PRS-080 has been designed to target hepcidin for the treatment of functional iron deficiency (FID) in anemic patients with chronic kidney disease (CKD) in end-stage renal disease patients requiring dialysis. PRS-060 is a drug candidate that binds to the IL-4RA receptor thereby inhibiting IL-4 and IL-13 two cytokines small proteins mediating signaling between cells within the human body which are mediators in the inflammatory cascade that causes asthma and other inflammatory diseases. It is also developing PRS-110 in cMet-related cancer and PRS-300 series.